Endotherapy: Dr. Geffard’s therapeutic revolution
It’s December 10, 1992, at the Collège de France, when the Bernard Halpern Prize is awarded. Prof. Jean Bernard was full of praise when he presented the prize to Dr. Michel Geffard:
“Some researchers devote themselves heroically to the study of spontaneously curable diseases. Michel Geffard is different. His work focuses on serious, poorly understood diseases.
The award recognizes the entire body of research carried out by Dr. Geffard, a physician and researcher (he holds a doctorate in medicine and a doctorate in science, and is a former director of research at Inserm), as well as his inquisitive and daring approach.
An astonishing discovery
Throughout his career, Dr. Geffard has researched the origins of serious and chronic diseases by studying the blood of patients suffering from multiple sclerosis (MS). And he did so at the request of numerous doctors, mainly neurologists. These doctors would send the blood of their MS patients to Dr. Geffard’s laboratory for study. For Dr. Geffard had an international reputation as THE specialist in the detection of antibodies against non-antigenic molecules, neuromediators that had previously been immunologically undetectable. Dr. Geffard’s expertise in immunology enabled him to identify the existence in the blood of these patients of antibodies against Gram-negative bacteria (intestinal bacteria).
The spectacular effects of endotherapy on patient health
The following diagram compares the condition of MS patients treated with conventional therapies (red curve) with that of a man with MS who benefited from endotherapy over a 7-year period (blue curve). The reference scale is the functional deficit, also known as the EDSS score. The score ranges from 0 (no neurological deficit) to 10 (death).
Need more information and to meet Dr. Pascal Trotta?
Make an appointmentAlso read
Your iris, a unique work of art for getting to know you better
Waves that heal